PARP inhibitors , including olaparib and niraparib , impair DNA repair in BRCA-mutated cells and are approved for ovarian, breast, pancreatic, and prostate cancers
Explains the treatment process and designs a treatment plan based on your needs
Tolerability: Studies have shown no significant side effects at doses up to 3,600 mg/day
[DOI] [PMC free article] [PubMed] [Google Scholar] 25.Gwon A.-R., Park J.-S., Arumugam T.V., Kwon Y.-K., Chan S.L., Kim S.H., Baik S.H., Yang S., Yun Y.K., Choi Y., et al
Besides, only a very small portion of the overall inherited risk remains defined by the major depressive polygenic risk rating determined by these genetic locations (191)